Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines

We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Royalty Pharma plc is one of them.

Royalty Pharma plc (NASDAQ:RPRX) is a leading biopharmaceutical royalty company that invests in and acquires royalty interests in innovative drug products, partnering with biotech firms, pharmaceutical companies, and research institutions. The company funds late-stage clinical trials and new product launches in exchange for future royalty revenues.

In August 2025, the business reported strong Q2 results, with Portfolio Receipts rising 20% to $727 million and Royalty Receipts up 11%, driven by products such as Voranigo, Trelegy, Evrysdi, and Tremfya. Full-year 2025 guidance for Portfolio Receipts was raised to $3.05–$3.15 billion, reflecting expected growth of 9%–12%.

A key milestone was the May 2025 acquisition of its external manager, RP Management, LLC, creating an integrated public company that streamlines operations and combines its royalty portfolio with intellectual capital. For investors exploring growth opportunities in healthcare, particularly beyond cheap biotech stocks to buy, Royalty Pharma plc (NASDAQ:RPRX) stands out by offering exposure to a diversified royalty portfolio rather than relying on individual drug developers. The company also acquired a royalty interest in Amgen’s Imdelltra, a DLL3-targeting bispecific T-cell engager for small cell lung cancer, for $885 million upfront, with options for additional royalties up to $65 million, expanding its oncology portfolio.

Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines

Royalty Pharma plc (NASDAQ:RPRX) entered a $2 billion funding partnership with Revolution Medicines for the development of daraxonrasib, a Phase 3 cancer therapy, including a synthetic royalty of up to $1.25 billion while allowing the partner to retain control over pipeline development. Positive clinical updates from partners, including Phase 3 results for Gilead’s Trodelvy in metastatic triple-negative breast cancer, continue to enhance the value and growth potential of the corporation’s royalty assets.

While we acknowledge the risk and potential of RPRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RPRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.